Evaluating Herbicides for the Control of Multiflora Rose and Autumn Olive in Eastern Ohio

Invasive plants cause billions of dollars annually in damage, displace desirable plants, and reduce available land area for livestock grazing. Multiflora rose and autumn olive are two such species prevalent across the Eastern United States. Originally introduced for livestock containment and erosion control, these plants have become widespread, resulting in reduced animal grazing. The Eastern Agricultural Research Station (EARS) is located in Southeast Ohio and is owned by The Ohio State University. Much of the more than 2,000 acres has a history of surface mining and was reclaimed with the planting of multiflora rose and autumn olive. These plants have invaded significant portions of the property and have reduced land available to support the commercial beef research herd. Our study included a replicated trial of multiflora rose and autumn olive plants. We categorized plants into small and medium/large sizes across the study area. Six herbicide treatments were applied to plants using a handheld sprayer. Herbicide treatments were applied randomly in August and an assessment was completed approximately six weeks to rate effectiveness of the applications as compared to the control plants. There were four replicates per treatment. The initial results of the first year of the study indicate each of the products tested provided acceptable control of the treated plants

Localization of apoptosis proteins and lymphocyte subsets in chronic rejection of human liver allograft

L

Ohio Pastures for Profit Online

The Pastures for Profit program is an established course created through a collaboration between Ohio State University Extension, Central State University, USDA-Natural Resources Conservation Service, Ohio Federation of Soil and Water Conservation Districts, Ohio Department of Agriculture, and the Ohio Forage and Grasslands Council. In 2021, due to COVID-19, the Pastures for Profit curriculum was adapted to a virtual classroom setting and was offered again in 2022. The virtual experience consisted of three live webinars pairing with corresponding modules in Scarlet Canvas. Enrolled students were also mailed traditional course materials for personal use. Module content was newly developed and compiled to compliment the traditional materials and included videos, quizzes, additional presentations, and technical resources. The course materials were organized and taught by a team of over 50 collaborators. During the three live webinars, nearly 20 speakers presented on topics including the basics of grazing, plant and animal science, and grazing plans. A total of 168 people enrolled in Scarlet Canvas in the two-year time frame from over 15 states and included producers, educators, technical service providers, and government agency staff. Each live session was recorded and made available to the class for access at their convenience. Those who completed the course obtained a signed certificate of completion. This platform allowed for an expanded audience reach than in the past

Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study

<p>Abstract</p> <p>Background</p> <p>Infliximab (IFX) has proven to be an effective addition to the therapeutic arsenal for refractory, fistulizing, and steroid dependent Crohn's disease (CD), with efficacy in the induction and maintenance of clinical remission of CD. Our objective in this study is to report the nationwide, multicenter experience with IFX induction therapy for CD in Hungary.</p> <p>Methods</p> <p>During a 6-year-period, beginning in 2000, a total of 363 CD patients were treated with IFX as induction therapy (5 mg/kg IFX infusions given at week 0, 2 and 6) at eleven centers in Hungary in this observational study. Data analysis included patient demographics, important disease parameters and the outcome of IFX induction therapy.</p> <p>Results</p> <p>Three hundred and sixty three patients (183 women and 180 men) were treated with IFX since 2000. Mean age was 33.5 ± 11.2 years and the mean duration of disease was 6.7 ± 6.1 years. The population included 114 patients (31.4%) with therapy-refractory CD, 195 patients (53.7%) with fistulas, 16 patients (4.4%) with both therapy-refractory CD and fistulas, and 26 patients (7.2%) with steroid dependent CD. Overall response rate was 86.2% (313/363). A higher response rate was observed in patients with shorter disease duration (p = 0.05, OR:0.54, 95%CI:0.29-0.99) and concomitant immunosuppressant therapy (p = 0.05, OR: 2.03, 95%CI:0.165-0.596). Concomitant steroid treatment did not enhance the efficacy of IFX induction therapy. Adverse events included 34 allergic reactions (9.4%), 17 delayed type hypersensitivity (4.7%), 16 infections (4.4%), and 3 malignancies (0.8%).</p> <p>Conclusion</p> <p>IFX was safe and effective treatment in this cohort of Hungarian CD patients. Based on our experience co-administration of immunosuppressant therapy is suggested in patients receiving IFX induction therapy. However, concomitant steroid treatment did not enhanced the efficacy of IFX induction therapy.</p

Activity of Ulcerative Colitis Before and After Liver Transplantation in Primary Sclerosing Cholangitis: the Hungarian Experience

L